A judge overseeing a competition class action against Queensland power companies Stanwell and CS Energy has warned that judges need to be inventive in how they manage large group proceedings, otherwise the âsystem will collapseâ.
In a class action long delayed by a battle over foreign shareholders, BHP Group has finally filed a defence, denying it misled shareholders over a failed Brazilian dam and saying knowledge about the risk of collapse cannot be imputed to the Melbourne-headquartered energy giant.
Johnson Winter Slattery has lured a long time Corrs Chambers Westgarth lawyer to join its real estate team in Melbourne as a special counsel.
An investor class action has reached a settlement with four former directors of defunct Linchpin Capital, leaving only allegations against AIG Insurance, which is allegedly seeking to withdraw an admission that directors were insured under a D&O policy.Â
A group member in a class action against J&J unit Depuy International can receive compensation for out of pocket expenses associated with an alleged defective knee implant, despite having been paid by WorkSafe Victoria, a court has found.
The insurers of Blue Sky Alternative Investments are fighting a bid to be joined to a consolidated investor class action against the company and its auditor, EY.
Fox News CEO Lachlan Murdoch wants a court to decide before trial whether a Crikey article published last year that allegedly linked him to the US Capital riot was defamatory.Â
The Australian Competition and Consumer Commission and Mazda have both lost their appeals in a case over the car manufacturerâs âappallingâ customer service, with three judges questioning the regulatorâs decisions in how it ran the case.
App developers can be added as group members in class actions against Apple and Google alleging they engaged in anti-competitive conduct in operating their app stores, despite Appleâs concerns that the law firm running the case will owe conflicting duties.Â
German pharmaceutical giant Bayer has slammed generic drug make Sandozâs late bid for documents, which it called an attempt to âdivert and distractâ Bayer on the eve of a three-week trial over the patents for its top-selling blood clot drug Xarelto.